Skip to content
Open access

Treatment Outcomes of Patients with Early-Stage Breast Cancer Meeting NATALEE Eligibility Criteria. A Real-World Cohort Study

Oct 2026 · Drug Design, Development and Therapy · Vol 20 · 0 citations · 39 references
Medicine

TL;DR

The findings provide real-world historical outcome data for patients who would now be considered candidates for adjuvant ribociclib and may serve as a benchmark for evaluating outcomes following adoption of adjuvant ribociclib.

Abstract

Purpose Adjuvant CDK4/6 inhibitors have demonstrated significant disease-free survival (DFS) benefits in high-risk early-stage hormone receptor (HR)-positive /HER2-negative breast cancer. However, real-world outcome data describing patients who would meet contemporary eligibility criteria remain limited. This study evaluates treatment outcomes in patients retrospectively classified as eligible for adjuvant ribociclib treatment. Patients and Methods A retrospective cohort analysis was conducted using clinical data from patients with early-stage HR-positive/HER2-negative breast cancer. Eligibility for adjuvant ribociclib was assigned using the NATALEE trial-based criteria. Differences in treatment outcomes in those eligible versus ineligible patients are reported. Results Among the 2730 patients included, 1,955 (71.6%) were high risk and would have met NATALEE eligibility, including 1,679 (85.9%) with node-positive disease, 602 (30.8%) with cT3-4 tumors, and 686 (35.1%) with grade 3 disease; 775 (28.4%) were ineligible due to lower-risk features. Across the cohort, the 5-year DFS rate was significantly worse in CDK4/6i-eligible patients compared to those deemed ineligible: 78.4% versus 91.5% (HR=2.51; 95% CI: 2.01–3.14; p<0.0001). Though median OS was not reached, survival curve separation became evident by 36 months and widened progressively. Multivariable Cox regression identified low/intermediate ER expression (<50%), node-positive disease, larger tumors (cT3-4), and grade 3 histology as independent predictors of worse overall survival. Low/intermediate ER expression was associated with significantly poorer OS (HR 1.85, 95% CI 1.27–2.70; p=0.001), while lower-grade and smaller tumors were associated with improved survival. Conclusion A significant proportion of patients in this real-world cohort would have met criteria for adjuvant CDK4/6 inhibition. These patients experienced worse survival outcomes compared to their ineligible counterparts. These findings provide real-world historical outcome data for patients who would now be considered candidates for adjuvant ribociclib and may serve as a benchmark for evaluating outcomes following adoption of adjuvant ribociclib.

Read PDF

Similar papers

Open access Oct 2026

Characteristics and outcomes of NATALEE- and monarchE-eligible early breast cancer in Finland: a regional real-world cohort study

Real-world outcomes among NATALEE and monarchE-eligible patients are consistent with results from phase III trial comparator arms, and both NATALEE and monarchE eligibility were associated with distant metastasis, and mortality.

S. Voutilainen, S. Tuominen, L. Ukkola-Vuoti et al. · 0 citations
Open access Sep 2026

Real-world treatment patterns and associated outcomes in patients with HER2-positive unresectable or metastatic breast cancer: the HER2 REAL Study

This retrospective study shows heterogeneity in treatment patterns and survival outcomes in real-world patients with HER2-positive mBC, indicating the need for optimization of treatment in patients with HER2-positive mBC in real-world.

S. C. Lee, C. Barrios, W. Chung et al. · 0 citations
Open access Sep 2026

A retrospective, observational cohort study of treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States following endocrine therapy

The findings reinforce the high unmet need in patients with HR+/HER2’s metastatic breast cancer whose disease has become resistant to ET, highlighting the need for effective treatments in this setting.

J. O'Shaughnessy, M. Rehnquist, N. Sadetsky et al. · 0 citations
Open access Nov 2026

Adjuvant Docetaxel–Cyclophosphamide Versus Anthracycline–Taxane Chemotherapy in Stage I–III HR-Positive/HER2-Negative Breast Cancer: A Real-World Propensity Score Overlap-Weighted Cohort Study

Findings support individualized adjuvant chemotherapy selection and warrant confirmation in larger cohorts with longer follow-up, particularly regarding the incremental benefit of anthracyclines.

Perihan Perkin, D. Sarikaya, H. Karakaş et al. · 0 citations
Open access 2026

Adjuvant capecitabine in residual triple-negative breast cancer after carboplatin-based neoadjuvant chemotherapy: a real-world cohort

Introduction: Patients with triple-negative breast cancer (TNBC) who do not achieve pathologic complete response (pCR) after neoadjuvant chemotherapy have a worse prognosis. Adjuvant capecitabine has demonstrated benefit in selected populations, but its role after prior carboplatin exposure remains uncertain, particula...

G. Tavares, S. Ramalho, L. Silva et al. · 0 citations
Oct 2026

21-Gene recurrence score assay in pN2-3 Early-Stage breast cancer: a national cancer database study.

BACKGROUND The clinical utility of the 21-gene recurrence score (RS) for guiding adjuvant chemotherapy in patients with pN2-3 early-stage breast cancer (eBC) has not been evaluated in prospective trials. This study aims to assess adjuvant chemotherapy benefit in patients with pN2-3 eBC who underwent RS testing and had...

C. Valenza, Yue Zheng, J. P. Leone et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.